Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML
Study Details
Study Description
Brief Summary
The purpose of the study is to determine if metformin in combination with cytarabine is safe and effective. Participants in this research study have acute myeloid leukemia (AML) that has come back after initial treatment or has not gone away with initial therapy.There is evidence that metformin directly kills leukemia cells. Laboratory data have also shown that combinations of metformin with cytarabine are more efficient than each agent alone in killing leukemia cells in the laboratory.
Detailed Description
PRIMARY OBJECTIVES:
-
Determine the maximum tolerated dose (MTD) of metformin (metformin hydrochloride) in combination with cytarabine in relapsed/refractory AML.
-
Define the dose limiting toxicity (DLT) of metformin in combination with cytarabine in relapsed/refractory AML.
SECONDARY OBJECTIVES:
- Remission rate. II. Overall survival (OS). III. Disease-free survival (DFS). IV. Length of remission.
OUTLINE: This is a dose-escalation study of metformin hydrochloride in combination with Cytarabine.
Patients receive metformin hydrochloride orally (PO) twice daily (BID) on days 1-15 and cytarabine intravenously (IV) over 3 hours BID on days 4-10.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 5 years.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Treatment (enzyme inhibitor and chemotherapy) Patients receive metformin hydrochloride orally twice a day on days 1-15 and cytarabine IV over 3 hours twice on days 4-10. |
Drug: metformin hydrochloride
Given orally
Other Names:
Drug: cytarabine
Given IV
Other Names:
Other: laboratory biomarker analysis
Correlative studies
|
Outcome Measures
Primary Outcome Measures
- Evaluate Toxicity by Assessing the Adverse Events of Metformin and Cytarabine [Checked daily during administration of cytarabine and at least 2x weekly following therapy until desired blood counts acheived (maximum 15 days)]
To determine the maximum tolerated dose (MTD) by assessing the adverse events of metformin in combination with cytarabine in evaluating toxicity. Assessments will occur daily during cytarabine administration and at least twice weekly following treatment until blood count recovery.
- Study Treatment Dose Toxicity Will be Evaluated by Measurement of Adverse Events Experienced While on Treatment [Checked daily during administration of cytarabine and at least 2x weekly following therapy until desired blood counts acheived (maximum 15 days)]
Determination of Dose Limiting Toxicity (DLT) as evidenced by adverse events due to toxicity from study treatment. If no DLT is observed, then 3 patients will be enrolled in the next dose escalated cohort. If one DLT is seen in the first 3 patients, then an additional 3 patients will be enrolled at the same dose cohort. If 0-1 in 6 patients experience a DLT this dose will be considered tolerable and the next dose escalated cohort with enroll 3 patients. If 2 or more in 6 patients experience a DLT, the maximum tolerated dose (MTD) will have been exceeded and the next cohort will enroll 3 patients at a reduced dose.
Secondary Outcome Measures
- Remission Rate [Every 3 months for 2 years, and then every 6 months for 5 years post-treatment]
Patients will be evaluated for remission status in response to therapy.
- Overall Survival [Every 3 months for 2 years, and then every 6 months for 5 years post-treatment]
Patients will be followed-up with from the initiation of study treatment until progression of disease or for up to 5 years, whichever comes first.
- Disease-free Survival [Every 3 months for 2 years, and then every 6 months for 5 years post-treatment]
Evaluation of Disease-Free Survival will defined as the time from the initiation of study treatment until the time of disease relapse.
- Length of Remission [From date of remission of disease to date of relapse (maximum of 5 year follow-up)]
Patients will be followed-up with to determine Remission length which is defined as the time from attainment of remission to relapse of disease.
Other Outcome Measures
- Bone Marrow and Blood Samples Will be Taken Prior to Study Treatment to Determine Number of Leukemic Progenitor Cells [At baseline prior to study treatment]
- Immunoblotting [At baseline prior to study treatment]
Bone marrow and/or blood samples taken prior to initiation of treatment will be used in Immunoblotting studies to observe enzyme and protein activity.
- Identical Immunoblotting [At baseline prior to study treatment]
Identical immunoblotting studies may also be performed using blood samples taken prior to start of treatment.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with relapsed/refractory disease must have morphologic proof (from bone marrow aspirate, smears or touch preps of bone marrow biopsy) of AML with >= 10% blasts within two weeks (14 days) prior to initiation of therapy
-
All immunophenotype and cytogenetic/molecular groups are eligible for participation except for acute promyelocytic leukemia (APL) (as proven by the presence of promyelocytic leukemia/retinoic acid receptor alpha [PML-RARĪ±])
-
Patients must demonstrate one of the following:
-
Relapse after first complete remission
-
Refractory to conventional induction chemotherapy (failure to respond to 1 or more cycles of daunorubicin and cytarabine) or to re-induction
-
Patients with previously untreated AML are candidates if they are unable to receive anthracyclines, and have documented AML with >= 20% blasts within one week prior to enrollment
-
Patients with chronic myelogenous leukemia (CML) in myeloid blast crisis are eligible if their disease has failed to respond, and/or they are intolerant, to the available tyrosine kinase inhibitors (TKIs)
-
Serum total and direct bilirubin =< upper limit of normal (ULN)
-
Serum creatinine < 1.4 mg/dl in females and < 1.5 mg/dl in males, and creatinine clearance > 60 mL/min
-
Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST])/serum glutamic pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< ULN
-
Bicarbonate within the normal range of the hospital lab (24-32 mmol/L)
-
Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
-
Females of childbearing potential and sexually active males must agree to use an accepted and effective method of contraception while on study
-
Childbearing potential is defined as any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
-
Has NOT undergone a hysterectomy or bilateral oophorectomy; OR
-
Has NOT been naturally postmenopausal for at least 12 consecutive months (i.e. has had menses at any time in the preceding 12 consecutive months)
-
Patients with a history of central nervous system (CNS) leukemia are eligible if they are not symptomatic from current CNS involvement
-
If there is CNS involvement that is known prior to enrollment or identified subsequently, it will be treated accordingly
-
Patients may have received therapy for other malignancies, as long as they have completed therapy at least 6 months prior to study entry and be deemed to have a life expectancy of at least 2 years with regard to that malignancy
-
All patients must have given signed, informed consent prior to registration on study
Exclusion Criteria:
-
Patients who have received chemotherapy or radiotherapy within 4 weeks prior to enrollment are NOT eligible for participation
-
The exception to this is patients who are refractory to conventional initial induction chemotherapy (=< 2 courses) or to first radiation (1 course); patients must have morphologic proof (from bone marrow aspirate, smears, or touch preps of marrow biopsy) of AML with > 10% blasts within 2 weeks prior to initiation of study therapy; the last dose of cytotoxic therapy (NOT including hydrea, which is allowed) must have been given >= 14 days prior to initiation of study therapy
-
Patients with a history of diabetes mellitus (DM) treated with metformin are NOT eligible for participation
-
Patients who are pregnant or breast feeding are NOT eligible for participation due to the lack of knowledge regarding the effects of the drugs on the fetus and during breast feeding
-
Patients with any intercurrent organ damage or medical problems that would prohibit therapy are NOT eligible for participation
-
Patients with any active, uncontrolled infection are NOT eligible for participation
-
Patients who are receiving therapy for another active malignancy are NOT eligible for participation
-
The exception to this is squamous cell carcinoma or basal cell carcinoma of the skin
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Northwestern University | Chicago | Illinois | United States | 60611 |
Sponsors and Collaborators
- Northwestern University
Investigators
- Principal Investigator: Jessica Altman, MD, Northwestern University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NU 11H03
- NCI-2011-01084
- STU00048047
Study Results
Participant Flow
Recruitment Details | The study opened for accrual July 29, 2013 with an accrual goal of between 19 to 28 participants in a 3 + 3 dose escalation design to find the maximum tolerated dose of metformin in combination with cytarabine. The study was closed permanently on January 21 2016 due to slow accrual. |
---|---|
Pre-assignment Detail |
Arm/Group Title | Treatment (Enzyme Inhibitor and Chemotherapy) |
---|---|
Arm/Group Description | Patients receive metformin hydrochloride orally twice a day on days 1-15 and cytarabine IV over 3 hours twice on days 4-10. metformin hydrochloride: Given orally cytarabine: Given IV laboratory biomarker analysis: Correlative studies |
Period Title: Registered to the Study | |
STARTED | 2 |
COMPLETED | 2 |
NOT COMPLETED | 0 |
Period Title: Registered to the Study | |
STARTED | 2 |
COMPLETED | 2 |
NOT COMPLETED | 0 |
Period Title: Registered to the Study | |
STARTED | 2 |
COMPLETED | 0 |
NOT COMPLETED | 2 |
Baseline Characteristics
Arm/Group Title | Treatment (Enzyme Inhibitor and Chemotherapy) |
---|---|
Arm/Group Description | Patients receive metformin hydrochloride orally twice a day on days 1-15 and cytarabine IV over 3 hours twice on days 4-10. metformin hydrochloride: Given orally cytarabine: Given IV laboratory biomarker analysis: Correlative studies |
Overall Participants | 2 |
Age (Count of Participants) | |
<=18 years |
0
0%
|
Between 18 and 65 years |
1
50%
|
>=65 years |
1
50%
|
Sex: Female, Male (Count of Participants) | |
Female |
1
50%
|
Male |
1
50%
|
Ethnicity (NIH/OMB) (Count of Participants) | |
Hispanic or Latino |
1
50%
|
Not Hispanic or Latino |
1
50%
|
Unknown or Not Reported |
0
0%
|
Race (NIH/OMB) (Count of Participants) | |
American Indian or Alaska Native |
0
0%
|
Asian |
0
0%
|
Native Hawaiian or Other Pacific Islander |
0
0%
|
Black or African American |
1
50%
|
White |
1
50%
|
More than one race |
0
0%
|
Unknown or Not Reported |
0
0%
|
Region of Enrollment (participants) [Number] | |
United States |
2
100%
|
Outcome Measures
Title | Evaluate Toxicity by Assessing the Adverse Events of Metformin and Cytarabine |
---|---|
Description | To determine the maximum tolerated dose (MTD) by assessing the adverse events of metformin in combination with cytarabine in evaluating toxicity. Assessments will occur daily during cytarabine administration and at least twice weekly following treatment until blood count recovery. |
Time Frame | Checked daily during administration of cytarabine and at least 2x weekly following therapy until desired blood counts acheived (maximum 15 days) |
Outcome Measure Data
Analysis Population Description |
---|
Adverse events that were assessed to be either possibly or unlikely related to treatment on study (i.e. relationship between treatment and adverse event could not be ruled out) |
Arm/Group Title | Treatment (Enzyme Inhibitor and Chemotherapy) |
---|---|
Arm/Group Description | Patients receive metformin hydrochloride orally twice a day on days 1-15 and cytarabine IV over 3 hours twice on days 4-10. metformin hydrochloride: Given orally cytarabine: Given IV laboratory biomarker analysis: Correlative studies |
Measure Participants | 2 |
Grade 1 |
4
|
Grade 2 |
6
|
Grade 3 |
2
|
Grade 4 |
0
|
Title | Study Treatment Dose Toxicity Will be Evaluated by Measurement of Adverse Events Experienced While on Treatment |
---|---|
Description | Determination of Dose Limiting Toxicity (DLT) as evidenced by adverse events due to toxicity from study treatment. If no DLT is observed, then 3 patients will be enrolled in the next dose escalated cohort. If one DLT is seen in the first 3 patients, then an additional 3 patients will be enrolled at the same dose cohort. If 0-1 in 6 patients experience a DLT this dose will be considered tolerable and the next dose escalated cohort with enroll 3 patients. If 2 or more in 6 patients experience a DLT, the maximum tolerated dose (MTD) will have been exceeded and the next cohort will enroll 3 patients at a reduced dose. |
Time Frame | Checked daily during administration of cytarabine and at least 2x weekly following therapy until desired blood counts acheived (maximum 15 days) |
Outcome Measure Data
Analysis Population Description |
---|
The study was terminated early due to slow accrual, thus insufficient data was collected to be analysed. |
Arm/Group Title | Treatment (Enzyme Inhibitor and Chemotherapy) |
---|---|
Arm/Group Description | Patients receive metformin hydrochloride orally twice a day on days 1-15 and cytarabine IV over 3 hours twice on days 4-10. metformin hydrochloride: Given orally cytarabine: Given IV laboratory biomarker analysis: Correlative studies |
Measure Participants | 0 |
Title | Remission Rate |
---|---|
Description | Patients will be evaluated for remission status in response to therapy. |
Time Frame | Every 3 months for 2 years, and then every 6 months for 5 years post-treatment |
Outcome Measure Data
Analysis Population Description |
---|
The study was terminated early due to slow accrual. As a result no data was collected or analyzed for this outcome measure. |
Arm/Group Title | Treatment (Enzyme Inhibitor and Chemotherapy) |
---|---|
Arm/Group Description | Patients receive metformin hydrochloride orally twice a day on days 1-15 and cytarabine IV over 3 hours twice on days 4-10. metformin hydrochloride: Given orally cytarabine: Given IV laboratory biomarker analysis: Correlative studies |
Measure Participants | 0 |
Title | Overall Survival |
---|---|
Description | Patients will be followed-up with from the initiation of study treatment until progression of disease or for up to 5 years, whichever comes first. |
Time Frame | Every 3 months for 2 years, and then every 6 months for 5 years post-treatment |
Outcome Measure Data
Analysis Population Description |
---|
The study was terminated early due to slow accrual. As a result no data was collected or analyzed for this outcome measure. |
Arm/Group Title | Treatment (Enzyme Inhibitor and Chemotherapy) |
---|---|
Arm/Group Description | Patients receive metformin hydrochloride orally twice a day on days 1-15 and cytarabine IV over 3 hours twice on days 4-10. metformin hydrochloride: Given orally cytarabine: Given IV laboratory biomarker analysis: Correlative studies |
Measure Participants | 0 |
Title | Disease-free Survival |
---|---|
Description | Evaluation of Disease-Free Survival will defined as the time from the initiation of study treatment until the time of disease relapse. |
Time Frame | Every 3 months for 2 years, and then every 6 months for 5 years post-treatment |
Outcome Measure Data
Analysis Population Description |
---|
The study was terminated early due to slow accrual. As a result no data was collected or analyzed for this outcome measure. |
Arm/Group Title | Treatment (Enzyme Inhibitor and Chemotherapy) |
---|---|
Arm/Group Description | Patients receive metformin hydrochloride orally twice a day on days 1-15 and cytarabine IV over 3 hours twice on days 4-10. metformin hydrochloride: Given orally cytarabine: Given IV laboratory biomarker analysis: Correlative studies |
Measure Participants | 0 |
Title | Length of Remission |
---|---|
Description | Patients will be followed-up with to determine Remission length which is defined as the time from attainment of remission to relapse of disease. |
Time Frame | From date of remission of disease to date of relapse (maximum of 5 year follow-up) |
Outcome Measure Data
Analysis Population Description |
---|
The study was terminated early due to slow accrual. As a result no data was collected or analyzed for this outcome measure. |
Arm/Group Title | Treatment (Enzyme Inhibitor and Chemotherapy) |
---|---|
Arm/Group Description | Patients receive metformin hydrochloride orally twice a day on days 1-15 and cytarabine IV over 3 hours twice on days 4-10. metformin hydrochloride: Given orally cytarabine: Given IV laboratory biomarker analysis: Correlative studies |
Measure Participants | 0 |
Title | Bone Marrow and Blood Samples Will be Taken Prior to Study Treatment to Determine Number of Leukemic Progenitor Cells |
---|---|
Description | |
Time Frame | At baseline prior to study treatment |
Outcome Measure Data
Analysis Population Description |
---|
The study was terminated early due to slow accrual. As a result no data was collected or analyzed for this outcome measure. |
Arm/Group Title | Treatment (Enzyme Inhibitor and Chemotherapy) |
---|---|
Arm/Group Description | Patients receive metformin hydrochloride orally twice a day on days 1-15 and cytarabine IV over 3 hours twice on days 4-10. metformin hydrochloride: Given orally cytarabine: Given IV laboratory biomarker analysis: Correlative studies |
Measure Participants | 0 |
Title | Immunoblotting |
---|---|
Description | Bone marrow and/or blood samples taken prior to initiation of treatment will be used in Immunoblotting studies to observe enzyme and protein activity. |
Time Frame | At baseline prior to study treatment |
Outcome Measure Data
Analysis Population Description |
---|
The study was terminated early due to slow accrual. As a result no data was collected or analyzed for this outcome measure. |
Arm/Group Title | Treatment (Enzyme Inhibitor and Chemotherapy) |
---|---|
Arm/Group Description | Patients receive metformin hydrochloride orally twice a day on days 1-15 and cytarabine IV over 3 hours twice on days 4-10. metformin hydrochloride: Given orally cytarabine: Given IV laboratory biomarker analysis: Correlative studies |
Measure Participants | 0 |
Title | Identical Immunoblotting |
---|---|
Description | Identical immunoblotting studies may also be performed using blood samples taken prior to start of treatment. |
Time Frame | At baseline prior to study treatment |
Outcome Measure Data
Analysis Population Description |
---|
The study was terminated early due to slow accrual. As a result no data was collected or analyzed for this outcome measure. |
Arm/Group Title | Treatment (Enzyme Inhibitor and Chemotherapy) |
---|---|
Arm/Group Description | Patients receive metformin hydrochloride orally twice a day on days 1-15 and cytarabine IV over 3 hours twice on days 4-10. metformin hydrochloride: Given orally cytarabine: Given IV laboratory biomarker analysis: Correlative studies |
Measure Participants | 0 |
Adverse Events
Time Frame | Adverse events were collect cover a 7 month period before the study was terminated early due to slow accrual | |
---|---|---|
Adverse Event Reporting Description | ||
Arm/Group Title | Treatment (Enzyme Inhibitor and Chemotherapy) | |
Arm/Group Description | Patients receive metformin hydrochloride orally twice a day on days 1-15 and cytarabine IV over 3 hours twice on days 4-10. metformin hydrochloride: Given orally cytarabine: Given IV laboratory biomarker analysis: Correlative studies | |
All Cause Mortality |
||
Treatment (Enzyme Inhibitor and Chemotherapy) | ||
Affected / at Risk (%) | # Events | |
Total | 2/2 (100%) | |
Serious Adverse Events |
||
Treatment (Enzyme Inhibitor and Chemotherapy) | ||
Affected / at Risk (%) | # Events | |
Total | 2/2 (100%) | |
Gastrointestinal disorders | ||
Gastric perforation | 1/2 (50%) | 1 |
Hepatobiliary disorders | ||
Other-Transminitis | 1/2 (50%) | 1 |
Infections and infestations | ||
Sepsis | 1/2 (50%) | 1 |
Other (Not Including Serious) Adverse Events |
||
Treatment (Enzyme Inhibitor and Chemotherapy) | ||
Affected / at Risk (%) | # Events | |
Total | 2/2 (100%) | |
Blood and lymphatic system disorders | ||
Anemia | 1/2 (50%) | 1 |
Febrile neutropenia | 1/2 (50%) | 1 |
Thrombocytopenia | 1/2 (50%) | 1 |
Elevated D-Dimer | 1/2 (50%) | 1 |
Elevated INR | 1/2 (50%) | 1 |
Eye disorders | ||
Blurred vision | 1/2 (50%) | 1 |
Gastrointestinal disorders | ||
Diarrhea | 1/2 (50%) | 1 |
Lower gastrointestinal hemorrhage - Hematochezia | 1/2 (50%) | 1 |
General disorders | ||
Fever | 1/2 (50%) | 5 |
Infections and infestations | ||
Pleural infection | 1/2 (50%) | 1 |
Investigations | ||
Alanine aminotransferase increased | 1/2 (50%) | 1 |
Aspartate aminotransferase increased | 1/2 (50%) | 1 |
Weight loss | 1/2 (50%) | 3 |
White blood cell decreased | 1/2 (50%) | 1 |
Metabolism and nutrition disorders | ||
Hyperglycemia | 1/2 (50%) | 1 |
Hypoalbuminemia | 1/2 (50%) | 2 |
Hypoalbuminema | 1/2 (50%) | 7 |
Musculoskeletal and connective tissue disorders | ||
Chest wall pain | 1/2 (50%) | 1 |
Renal and urinary disorders | ||
Dysuria | 1/2 (50%) | 1 |
Urinary tract infection | 1/2 (50%) | 1 |
Reproductive system and breast disorders | ||
Symptomatic Bartholin gland | 1/2 (50%) | 1 |
Respiratory, thoracic and mediastinal disorders | ||
Epistaxis | 1/2 (50%) | 1 |
Cough | 1/2 (50%) | 1 |
Pneumonitis | 1/2 (50%) | 1 |
Dyspnea | 1/2 (50%) | 1 |
Vascular disorders | ||
Thromboembolic event | 1/2 (50%) | 1 |
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
Name/Title | Dr. Jessica Altman |
---|---|
Organization | Northwestern University |
Phone | 312-503-1761 |
J-altman@northwestern.edu |
- NU 11H03
- NCI-2011-01084
- STU00048047